Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB1 | P05556 | 2/20 | 0.39 |
| ▸ | ITGA4 | P13612 | 2/20 | 0.39 |
| ▸ | GLP1R | P43220 | 8/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | TNKS | O95271 | 2/20 | 0.36 |
| ▸ | F2 | P00734 | 1/20 | 0.36 |
| ▸ | PRCP | P42785 | 1/20 | 0.35 |
| ▸ | REN | P00797 | 1/20 | 0.35 |
| ▸ | CCKAR | P32238 | 1/20 | 0.35 |
| ▸ | CCKBR | P32239 | 1/20 | 0.35 |
| ▸ | APLNR | P35414 | 1/20 | 0.35 |
| ▸ | MMP1 | P03956 | 1/20 | 0.34 |
| ▸ | MMP3 | P08254 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21350916 | 0.89 | TSHR (0.39) | ITGB1ITGA4POLBTSHRF2 | |
| SCHEMBL21350917 | 0.88 | APLNR (0.40) | ITGB1ITGA4POLBTSHRF2 | |
| SCHEMBL21339798 | 0.88 | MMP3 (0.43) | ITGB1ITGA4POLBTSHRREN | |
| SCHEMBL21166968 | 0.85 | ITGB3 (0.41) | ITGB1ITGA4POLBTSHRF2 | |
| SCHEMBL21339696 | 0.84 | TSHR (0.50) | ITGB1ITGA4POLBTSHRTNKS | |
| SCHEMBL21339761 | 0.84 | REN (0.48) | ITGB1ITGA4TNKSPRCPREN | |
| SCHEMBL21350915 | 0.83 | ITGB1 (0.42) | ITGB1ITGA4TNKSF2APLNR | |
| SCHEMBL21350914 | 0.81 | ITGB1 (0.42) | ITGB1ITGA4F2RENAPLNR | |
| SCHEMBL21339704 | 0.79 | MMP3 (0.40) | POLBTSHRTNKSRENAPLNR | |
| SCHEMBL19681264 | 0.77 | POLB (0.44) | POLBTSHRF2APLNRMMP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11633460-B2 | Injectable solution at pH 7 comprising at least one basal insulin wherein the pI is comprised from 5.8 to 8.5 and a co-polyamino acid bearing carboxylate charges and hydrophobic radicals | ADOCIA (FR) | 2023-04-25 | — | — | US | disclosed |
| US-20220409523-A1 | COMPOSITIONS IN THE FORM OF AN INJECTABLE AQUEOUS SOLUTION COMPRISING AMYLIN, AN AMYLIN RECEPTOR AGONIST OR AN AMYLIN ANALOG AND A CO-POLYAMINO ACID | ADOCIA (FR) | 2022-12-29 | — | — | US | disclosed |
| US-11173109-B2 | Compositions in the form of an injectable aqueous solution comprising amylin, an amylin receptor agonist or an amylin analog and a co-polyamino acid | ADOCIA (FR) | 2021-11-16 | — | — | US | disclosed |
| US-10987426-B2 | Compositions in the form of an injectable aqueous solution comprising human glucagon and a co-polyamino acid | ADOCIA (FR) | 2021-04-27 | — | — | US | disclosed |
| US-20190274954-A1 | Copositions in the form of an injectable aqueous solution comprising amylin, an amylin receptor agonist or an amylin analog and a co-polyamino acid | ADOCIA (FR) | 2019-09-12 | — | — | US | disclosed |
| US-20190275115-A1 | INJECTABLE SOLUTION AT PH 7 COMPRISING AT LEAST ONE BASAL INSULIN WHEREIN THE PI IS COMPRISED FORM 5.8 TO 8.5 AND A CO-POLYAMINO ACID BEARING CARBOXYLATE CHARGES AND HYDROPHOBIC RADICALS | ADOCIA (FR) | 2019-09-12 | — | — | US | disclosed |
| US-20190275156-A1 | COMPOSITIONS SOUS FORME D'UNE SOLUTION AQUEUSE INJECTABLE COMPRENANT DU GLUCAGON HUMAIN ET UN CO-POLYAMINOACIDE | ADOCIA (FR) | 2019-09-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11633460-B2 | Injectable solution at pH 7 comprising at least one basal insulin wherein the pI is comprised from 5.8 to 8.5 and a co-polyamino acid bearing carboxylate charges and hydrophobic radicals | IAPP, HBB, IGF1R | ITGB1 1825/4885ITGA4 3642/4885GLP1R 11/4885 |
| US-20190275156-A1 | COMPOSITIONS SOUS FORME D'UNE SOLUTION AQUEUSE INJECTABLE COMPRENANT DU GLUCAGON HUMAIN ET UN CO-POLYAMINOACIDE | GCG, GLP1R, GHSR | ITGB1 4817/4885ITGA4 4842/4885GLP1R 2/4885 |
| US-20190274954-A1 | Copositions in the form of an injectable aqueous solution comprising amylin, an amylin receptor agonist or an amylin analog and a co-polyamino acid | IAPP, GLP1R, INSR | ITGB1 3532/4885ITGA4 3047/4885GLP1R 2/4885 |
| US-20220409523-A1 | COMPOSITIONS IN THE FORM OF AN INJECTABLE AQUEOUS SOLUTION COMPRISING AMYLIN, AN AMYLIN RECEPTOR AGONIST OR AN AMYLIN ANALOG AND A CO-POLYAMINO ACID | IAPP, INSR, GLP1R | ITGB1 3146/4885ITGA4 2658/4885GLP1R 3/4885 |
| US-10987426-B2 | Compositions in the form of an injectable aqueous solution comprising human glucagon and a co-polyamino acid | GCG, GLP1R, GCGR | ITGB1 4428/4885ITGA4 4392/4885GLP1R 2/4885 |
| US-11173109-B2 | Compositions in the form of an injectable aqueous solution comprising amylin, an amylin receptor agonist or an amylin analog and a co-polyamino acid | IAPP, INSR, GLP1R | ITGB1 3329/4885ITGA4 2820/4885GLP1R 3/4885 |
| US-20190275115-A1 | INJECTABLE SOLUTION AT PH 7 COMPRISING AT LEAST ONE BASAL INSULIN WHEREIN THE PI IS COMPRISED FORM 5.8 TO 8.5 AND A CO-POLYAMINO ACID BEARING CARBOXYLATE CHARGES AND HYDROPHOBIC RADICALS | IAPP, GCG, HBB | ITGB1 2241/4885ITGA4 3570/4885GLP1R 16/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.